Abstract

BackgroundCatheter-based renal denervation (RDN) is a promising approach to treat hypertension, but innervation patterns limit the response to endovascular RDN and the post-procedural renal artery narrowing or stenosis questions the endovascular ablation strategy. This study was performed to investigate the anti-hypertensive and target organ protective effects of perivascular RDN in spontaneously hypertensive rats (SHR).MethodsSHR and normotensive Wistar-Kyoto (WKY) rats were divided into sham group (n = 10), radiofrequency ablation group (n = 20) in which rats received bilateral perivascular ablation with radiofrequency energy (2 watts), and chemical (10% phenol in 95% ethanol) ablation group (n = 12). The tail-cuff blood pressure was measured before the ablation and on day 14 and day 28 after the procedure. The plasma levels of creatinine, urea nitrogen, and catecholamines, urinary excretion of electrolytes and protein, and myocardial and glomerular fibrosis were analyzed and compared among the groups on day 28 after the procedure.ResultsWe identified that 2-watt is the optimal radiofrequency power for perivascular RDN in rats. Perivascular radiofrequency and chemical ablation achieved roughly comparable blood pressure reduction in SHR but not in WKY on day 14 and day 28 following the procedure. Radiofrequency-mediated ablation substantially destroyed the renal nerves surrounding the renal arteries of both SHR and WKY without damaging the renal arteries and diminished the expression of tyrosine hydroxylase, the enzyme marker for postganglionic sympathetic nerves. Additionally, perivascular radiofrequency ablation also decreased the plasma catecholamines of SHR. Interestingly, both radiofrequency and chemical ablation decreased the myocardial and glomerular fibrosis of SHR, while neither increased the plasma creatinine and blood urea nitrogen nor affected the urinary excretion of electrolytes and protein when compared to sham group.ConclusionsRadiofrequency-mediated perivascular RDN may become a feasible procedure against hypertension, and provide similar anti-hypertensive and target organ protective effects as does the chemical ablation.

Highlights

  • Catheter-based endovascular renal denervation (RDN) is a promising strategy for the treatment of resistant hypertension [1,2,3,4,5]

  • We identified that 2-watt is the optimal radiofrequency power for perivascular RDN in rats

  • Radiofrequency-mediated ablation substantially destroyed the renal nerves surrounding the renal arteries of both spontaneously hypertensive rats (SHR) and WKY without damaging the renal arteries and diminished the expression of tyrosine hydroxylase, the enzyme marker for postganglionic sympathetic nerves

Read more

Summary

Introduction

Catheter-based endovascular renal denervation (RDN) is a promising strategy for the treatment of resistant hypertension [1,2,3,4,5]. The SYMPLICITY HTN-3 [12], a randomized prospective blind clinical trial, failed to show benefits from RDN for patients with resistant hypertension as compared with a sham group, the RDN is not yet dead [13, 14]. Instead, this trial promotes the comprehensive mechanistic study on the effect of RDN in the treatment of hypertension. Tzafriri et al evaluated benefits of endovascular radiofrequency ablation in different types of renal neural network anatomy through investigating the nerve and ganglia distribution surrounding the renal artery [15] It demonstrated that innervation patterns may limit the response to endovascular ablation. This study was performed to investigate the anti-hypertensive and target organ protective effects of perivascular RDN in spontaneously hypertensive rats (SHR)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call